文献速递肝病

免疫抑制兔模型建立慢性HEV感染并揭示肝纤维化及不同疫苗接种策略的疗效差异

Immunocompromised rabbit model of chronic HEV reveals liver fibrosis and distinct efficacy of different vaccination strategies.
PubMed 文献 · Hepatology · 2022-03-30

本研究用环孢素A诱导免疫抑制兔,分别接种兔源HEV3、人源HEV3或HEV4,成功建立慢性HEV感染模型,观察到肝纤维化及先天与适应性免疫激活,且慢性化可能与T细胞免疫应答受抑有关;利巴韦林可清除感染;免疫抑制前完成接种对HEV3和HEV4均提供完全保护,免疫抑制期间接种仅部分保护且增加剂量未提高疗效。

要点

  • 环孢素A诱导的免疫抑制兔可建立慢性HEV3和HEV4感染,并出现肝纤维化。
  • 利巴韦林可有效清除免疫抑制兔的HEV感染。
  • 免疫抑制前接种对HEV3和HEV4完全保护,免疫抑制期间接种仅部分保护且加量未增效。

核心结论

  • 免疫抑制兔模型可模拟移植患者慢性HEV感染的关键特征包括肝纤维化,并揭示免疫抑制前与免疫抑制期间接种疫苗的疗效差异。
  • 该模型有助于理解慢性戊型肝炎发病机制及评估抗病毒药物和疫苗。

研究设计与样本

  • 用环孢素A诱导免疫抑制,兔分别接种兔源HEV3、人源HEV3或HEV4。
  • 在接种后13周内评估HEV标志物,并在接种后4、8或13周用苏木精-伊红和Masson染色评估病理变化。

主要发现

  • 免疫抑制兔成功建立慢性HEV感染,肝脏、肾脏、肠道、尿液和脑脊液样本中检测到HEV RNA和/或抗原。
  • 慢性感染动物表现出肝纤维化发展的典型特征,肝内转录组分析提示先天和适应性免疫均被激活。
  • HEV慢性化的建立可能归因于T细胞免疫应答受抑。
  • 利巴韦林可有效清除免疫抑制兔的HEV感染。
  • 免疫抑制前完成接种对HEV3和HEV4感染均提供完全保护,而免疫抑制期间接种仅部分保护,且增加或额外接种疫苗剂量未提高疗效。

关键数值与推荐

  • 原文未报告关键数值与推荐。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: HEV infection can lead to chronicity and rapid progression to liver fibrosis and cirrhosis in immunocompromised organ transplant recipients. Robust animal models are urgently needed to study the pathogenesis and test the efficacy of vaccines and antiviral drugs in immunosuppressed settings. APPROACH AND RESULTS: Cyclosporin A was used to induce immunosuppression. Rabbits were challenged with genotype 3 or 4 HEV (i.e., the rabbit-derived HEV3 and human-derived HEV3 or HEV4). We assessed HEV markers within 13 weeks post inoculation (wpi) and pathological changes by hematoxylin and eosin and Masson staining at 4, 8, or 13 wpi. Chronic HEV infection was successfully established in immunocompromised rabbits. HEV RNA and/or antigens were detected in the liver, kidney, intestine, urine, and cerebrospinal fluid samples. Chronically infected animals exhibited typical characteristics of liver fibrosis development. Intrahepatic transcriptomic analysis indicated activation of both innate and adaptive immunity. Establishment of HEV chronicity likely contributed to the inhibited T-cell immune response. Ribavirin is effective in clearing HEV infection in immunocompromised rabbits. Most interestingly, vaccination completed before immunosuppression conferred full protection against both HEV3 and HEV4 infections, but vaccination during immunosuppression was only partially protective, and the efficacy did not improve with increased or additional vaccine doses. CONCLUSIONS: The immunocompromised rabbit model of both chronic HEV3 and HEV4 infection that was established captured the key features of chronic HEV infection in transplant patients, including liver fibrogenesis, and revealed the distinct effectiveness of vaccination administered before or under immunosuppression. This rabbit model is valuable for understanding the pathogenesis of chronic hepatitis E, as well as for evaluating antiviral agents and vaccines.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. He Q, Zhang F, Shu J, et al. Immunocompromised rabbit model of chronic HEV reveals liver fibrosis and distinct efficacy of different vaccination strategies. Hepatology. 2022. PMID: 35278241. doi:10.1002/hep.32455

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。